ea0038p407 | Steroids | SFEBES2015
Weigel Marianne
, Hahner Stefanie
, Beier Daniela
, Zopf Kathrin
, Quinkler Marcus
Background: Mitotane is a strong inducer of hepatic CYP3A4 activity (cortisol metabolism) and increases cortisol-binding globulin (CBG). High hydrocortisone dosages are necessary in patients with adrenocortical cancer (ACC) on mitotane treatment. The newly modified release hydrocortisone has not been used in mitotane-treated ACC patients yet.Aim: To compare cortisol (serum and saliva), calculated free serum cortisol and ACTH levels in ACC patients on mit...